Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, Chen W, Chen X, Chng WJ, Choi JK, Colmenero I, Coupland SE, Cross NCP, De Jong D, Elghetany MT, Takahashi E, Emile JF, Ferry J, Fogelstrand L, Fontenay M, Germing U, Gujral S, Haferlach T, Harrison C, Hodge JC, Hu S, Jansen JH, Kanagal-Shamanna R, Kantarjian HM, Kratz CP, Li XQ, Lim MS, Loeb K, Loghavi S, Marcogliese A, Meshinchi S, Michaels P, Naresh KN, Natkunam Y, Nejati R, Ott G, Padron E, Patel KP, Patkar N, Picarsic J, Platzbecker U, Roberts I, Schuh A, Sewell W, Siebert R, Tembhare P, Tyner J, Verstovsek S, Wang W, Wood B, Xiao W, Yeung C, Hochhaus A (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 36:1703–19

Yang F, Long N, Anekpuritanang T, Bottomly D, Savage JC, Lee T, Solis-Ruiz J, Borate U, Wilmot B, Tognon C, Bock AM, Pollyea DA, Radhakrishnan S, Radhakrishnan S, Patel P, Collins RH, Tantravahi S, Deininger MW, Fan G, Druker B, Shinde U, Tyner JW, Press RD, McWeeney S, Agarwal A (2022) Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML. Blood 139:1208–1221

Article  CAS  PubMed  PubMed Central  Google Scholar 

Feurstein S, Trottier AM, Estrada-Merly N, Pozsgai M, McNeely K, Drazer MW, Ruhle B, Sadera K, Koppayi AL, Scott BL, Oran B, Nishihori T, Agrawal V, Saad A, Lindsley RC, Nakamura R, Kim S, Hu Z, Sobecks R, Spellman S, Saber W, Godley LA (2022) Germ line predisposition variants occur in myelodysplastic syndrome patients of all ages. Blood 140:2533–2548

Article  CAS  PubMed  PubMed Central  Google Scholar 

Makishima H, Saiki R, Nannya Y, Korotev S, Gurnari C, Takeda J, Momozawa Y, Best S, Krishnamurthy P, Yoshizato T, Atsuta Y, Shiozawa Y, Iijima-Yamashita Y, Yoshida K, Shiraishi Y, Nagata Y, Kakiuchi N, Onizuka M, Chiba K, Tanaka H, Kon A, Ochi Y, Nakagawa MM, Okuda R, Mori T, Yoda A, Itonaga H, Miyazaki Y, Sanada M, Ishikawa T, Chiba S, Tsurumi H, Kasahara S, Müller-Tidow C, Takaori-Kondo A, Ohyashiki K, Kiguchi T, Matsuda F, Jansen JH, Polprasert C, Blombery P, Kamatani Y, Miyano S, Malcovati L, Haferlach T, Kubo M, Cazzola M, Kulasekararaj AG, Godley LA, Maciejewski JP, Ogawa S (2023) Germ line DDX41 mutations define a unique subtype of myeloid neoplasms. Blood 141:534–549

Article  CAS  PubMed  Google Scholar 

Trottier AM, Feurstein S, Godley LA (2024) Germline predisposition to myeloid neoplasms: characteristics and management of high versus variable penetrance disorders. Best Pract Res Clin Haematol 37. https://doi.org/10.1016/j.beha.2024.101537

Simon L, Spinella JF, Yao CY, Lavallée VP, Boivin I, Boucher G, Audemard E, Bordeleau ME, Lemieux S, Hébert J, Sauvageau G (2020) High frequency of germline RUNX1 mutations in patients with RUNX1-mutated AML. Blood 135:1882–1886

Article  CAS  PubMed  Google Scholar 

Kanagal-Shamanna R, Loghavi S, Dinardo CD, Medeiros LJ, Garcia-Manero G, Jabbour E, Routbort MJ, Luthra R, Bueso-Ramos CE, Khoury JD (2017) Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation. Haematologica 102:1661–1670

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yu K, Deuitch N, Merguerian M, Cunningham L, Davis J, Bresciani E, Diemer J, Andrews E, Young A, Donovan F, Sood R, Craft K, Chong S, Chandrasekharappa S, Mullikin J, Liu PP (2023) Genomic landscape of patients with germline RUNX1 variants and familial platelet disorder with myeloid malignancy. Blood Adv 8:497

Article  PubMed Central  Google Scholar 

Asou N (2003) The role of a runt domain transcription factor AML1/RUNX1 in leukemogenesis and its clinical implications. Crit Rev Oncol Hematol 45:129–150

Article  PubMed  Google Scholar 

Wang C, Tu Z, Cai X, Wang W, Davis AK, Nattamai K, Paranjpe A, Dexheimer P, Wu J, Huang FL, Geiger H, Huang G, Zheng Y (2023) A critical role of RUNX1 in governing megakaryocyte-primed hematopoietic stem cell differentiation. Blood Adv 7:2590–2605

Article  CAS  PubMed  PubMed Central  Google Scholar 

Homan CC, Scott HS, Brown AL (2023) Hereditary platelet disorders associated with germ line variants in RUNX1, ETV6, and ANKRD26. Blood 141:1533–1543

Article  CAS  PubMed  PubMed Central  Google Scholar 

Choi EJ, Cho YU, Hur EH, Jang S, Kim N, Park HS, Lee JH, Lee KH, Kim SH, Hwang SH, Seo EJ, Park CJ, Lee JH (2022) Unique ethnic features of < I > DDX41 mutations in patients with idiopathic cytopenia of undetermined significance, myelodysplastic syndrome, or acute myeloid leukemia. Haematologica 107:510–518

Article  CAS  PubMed  Google Scholar 

Bannon SA, Routbort MJ, Montalban-Bravo G, Mehta RS, Jelloul FZ, Takahashi K, Daver N, Oran B, Pemmaraju N, Borthakur G, Naqvi K, Issa G, Sasaki K, Alvarado Y, Kadia TM, Konopleva M, Shamanna RK, Khoury JD, Ravandi F, Champlin R, Kantarjian HM, Bhalla K, Garcia-Manero G, Patel KP, DiNardo CD (2021) Next-generation sequencing of DDX41 in myeloid neoplasms leads to increased detection of germline alterations. Front Oncol 10:582213

Article  PubMed  PubMed Central  Google Scholar 

Kroger B, Ji Y, Thomas T, Madanat YF, Collins RH, Visconte V, Gurnari C, Maciejewski J, Chung S (2024) Bi-allelic DDX41 mutations exert Stage Specific effects on hematopoiesis to promote Disease. Blood 144:347–347

Article  Google Scholar 

Andrés-Zayas C, Suárez-González J, Rodríguez-Macías G, Dorado N, Osorio S, Font P, Carbonell D, Chicano M, Muñiz P, Bastos M, Kwon M, Díez-Martín JL, Buño I, Martínez-Laperche C (2021) Clinical utility of targeted next-generation sequencing for the diagnosis of myeloid neoplasms with germline predisposition. Mol Oncol 15:2273

Article  PubMed  PubMed Central  Google Scholar 

Godley LA (2023) Prioritization of patients for germline testing based on tumor profiling of hematopoietic malignancies. Front Oncol 13. https://doi.org/10.3389/FONC.2023.1084736/PDF

Baliakas P, Tesi B, Wartiovaara-Kautto U, Stray-Pedersen A, Friis LS, Dybedal I, Hovland R, Jahnukainen K, Raaschou-Jensen K, Ljungman P, Rustad CF, Lautrup CK, Kilpivaara O, Kittang AO, Gronbeak K, Cammenga J, Hellström-Lindberg E, Andersen MK (2019) Nordic guidelines for germline predisposition to myeloid neoplasms in adults: recommendations for genetic diagnosis, Clinical Management and follow-up. Hemasphere 3. https://doi.org/10.1097/HS9.0000000000000321

Li P, White T, Xie W, Cui W, Peker D, Zeng G, Wang HY, Vagher J, Brown S, Williams M, Kovacsovics T, Patel JL (2022) AML with germline DDX41 variants is a clinicopathologically distinct entity with an indolent clinical course and favorable outcome. Leukemia 36:664–674

Article  CAS  PubMed  Google Scholar 

Negoro E, Radivoyevitch T, Polprasert C, Adema V, Hosono N, Makishima H, Przychodzen B, Hirsch C, Clemente MJ, Nazha A, Santini V, McGraw KL, List AF, Sole F, Sekeres MA, Maciejewski JP (2016) Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide. Leuk 2016 30:12

Google Scholar 

Abou Dalle I, Kantarjian H, Bannon SA, Kanagal-Shamanna R, Routbort M, Patel KP, Hu S, Bhalla K, Garcia-Manero G, DiNardo CD (2020) Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation. Am J Hematol 95:227–229

Article  PubMed  Google Scholar 

Makishima H, Bowman TV, Godley LA (2023) DDX41-associated susceptibility to myeloid neoplasms. Blood 141:1544–1552

Article  CAS  PubMed  Google Scholar